Kogenate Bayer (octocog alfa)
- Region
- 🇪🇺 EU
- Active substance
- octocog alfa
- Company
- Bayer AG
- Status
- Lapsed
- Therapeutic area
- Hemophilia A
- EU approval
- Fri 04 Aug 2000
- Application
- EMEA/H/C/000275
- ATC
- B02BD02
- Official record
- www.ema.europa.eu
Indication
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Jivi Authorised · Bayer AG
- 🇪🇺 Afstyla Authorised · CSL Behring GmbH
- 🇪🇺 Altuvoct Authorised · Swedish Orphan Biovitrum AB (publ)
- 🇪🇺 Adynovi Authorised · Baxalta Innovations GmbH
- 🇪🇺 Elocta Authorised · Swedish Orphan Biovitrum AB (publ)
- 🇪🇺 Nuwiq Authorised · Octapharma AB
- 🇪🇺 Advate Authorised · Takeda Manufacturing Austria AG
- 🇪🇺 Kovaltry Authorised · Bayer AG
- 🇪🇺 Obizur Authorised · Baxalta Innovations GmbH
- 🇪🇺 ReFacto AF Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Esperoct Authorised · Novo Nordisk A/S
- 🇪🇺 Vihuma Authorised · Octapharma AB
Follow Kogenate Bayer
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.